IGM Biosciences, Inc. (IGMS) Bundle
A Brief History of IGM Biosciences
IGM Biosciences, Inc. is a clinical-stage biotechnology company founded in 2010, focusing on the development of engineered IgM antibodies for the treatment of autoimmune and inflammatory diseases. The company operates out of Mountain View, California, with additional facilities in Doylestown, Pennsylvania.
Financial Overview
As of September 30, 2024, IGM Biosciences reported the following financial results:
| Financial Metric | 2024 | 2023 |
|---|---|---|
| Net Loss (Nine Months Ended) | $159.1 million | $185.7 million |
| Accumulated Deficit | $980.4 million | $821.2 million |
| Cash, Cash Equivalents, and Marketable Securities | $218.8 million | $175.4 million |
| Collaboration Revenue | $2.3 million | $1.5 million |
| Research and Development Expenses | $131.9 million | $161.3 million |
| General and Administrative Expenses | $39.9 million | $38.5 million |
Recent Developments
In September 2024, IGM announced a strategic pivot to focus exclusively on autoimmunity, alongside a restructuring that included a workforce reduction. This restructuring is expected to extend the company's cash runway and is projected to be substantially complete by June 30, 2025. During this restructuring phase, the company recognized charges totaling $14.0 million, primarily related to severance and stock-based compensation expenses.
Research and Development Focus
IGM has prioritized its research efforts on developing therapies for autoimmune diseases while deprioritizing oncology programs. The company’s research and development spending for the nine months ended September 30, 2024, was $131.9 million, a decrease from $161.3 million in the same period of 2023. This reduction was largely attributed to decreased personnel costs and the winding down of certain clinical programs.
Operating Expenses
The breakdown of operating expenses for the nine months ended September 30, 2024, is as follows:
| Expense Type | 2024 | 2023 |
|---|---|---|
| Research and Development | $131.9 million | $161.3 million |
| General and Administrative | $39.9 million | $38.5 million |
| Total Operating Expenses | $171.9 million | $199.8 million |
Liquidity Position
As of September 30, 2024, IGM reported cash and cash equivalents amounting to $218.8 million. The company has projected that this liquidity will be sufficient to fund operations for at least one year beyond the date of the financial statements. However, the need for additional funding remains a critical concern as the company continues to operate at a loss, with no products approved for sale to date.
IGM's strategic focus, ongoing restructuring efforts, and financial metrics indicate a company in transition, aiming to stabilize its operations while navigating the complexities of the biotechnology landscape.
A Who Owns IGM Biosciences, Inc. (IGMS)
Ownership Structure
As of September 30, 2024, IGM Biosciences, Inc. (IGMS) has a total of 34,060,315 shares of common stock and 25,386,983 shares of non-voting common stock issued and outstanding. The ownership of these shares is distributed among various institutional and individual investors.
Major Shareholders
The following table provides a breakdown of the largest shareholders of IGM Biosciences as of 2024:
| Shareholder | Type of Ownership | Number of Shares Owned | Percentage of Total Shares |
|---|---|---|---|
| Sanofi | Institutional Investor | Approximately 6,187,500 | 18.2% |
| Vanguard Group | Institutional Investor | Approximately 3,500,000 | 10.3% |
| BlackRock, Inc. | Institutional Investor | Approximately 3,000,000 | 8.8% |
| FMR LLC (Fidelity) | Institutional Investor | Approximately 2,000,000 | 5.9% |
| Other Institutional Investors | Various | Approximately 10,000,000 | 29.4% |
| Insider Holdings | Management and Directors | Approximately 1,500,000 | 4.4% |
| Public Float | Retail Investors | Approximately 8,872,815 | 26.1% |
Institutional Ownership
Institutional investors hold a significant portion of IGM Biosciences' shares, reflecting confidence in the company's growth potential. The top institutional shareholders include:
- Sanofi: 6,187,500 shares
- Vanguard Group: 3,500,000 shares
- BlackRock, Inc.: 3,000,000 shares
- FMR LLC (Fidelity): 2,000,000 shares
Insider Ownership
Insiders, including executives and board members, hold approximately 1,500,000 shares, representing 4.4% of the total shares outstanding. This alignment of interests is critical for fostering shareholder confidence.
Stock Performance and Market Trends
As of September 30, 2024, IGM Biosciences had an accumulated deficit of $980.4 million. The company reported a net loss of $159.1 million for the nine months ended September 30, 2024. Despite these challenges, the stock's performance remains closely watched by analysts and investors, particularly in light of ongoing developments in clinical trials and partnerships, such as with Sanofi.
Conclusion
The ownership structure of IGM Biosciences, Inc. is characterized by a mix of institutional and retail investors, with significant stakes held by major institutional players. This diversified ownership base, combined with insider holdings, supports the company's strategic initiatives and long-term growth ambitions in the biotechnology sector.
IGM Biosciences, Inc. (IGMS) Mission Statement
Company Overview
IGM Biosciences, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutics for autoimmune and inflammatory diseases. The company's mission is to harness the power of its proprietary IgM antibody technology platform to create transformative therapies that can significantly improve patient outcomes.
Mission Statement
The mission statement of IGM Biosciences emphasizes their commitment to advancing the field of immunology by developing high-quality, targeted therapies. The company aims to deliver highly effective and safe treatment options for patients suffering from various autoimmune diseases.
Financial Overview
As of September 30, 2024, IGM Biosciences reported significant financial metrics that highlight its operational scale and research investment:
| Financial Metric | Value (in thousands) |
|---|---|
| Net Loss for Nine Months Ended September 30, 2024 | $159,148 |
| Net Loss for Nine Months Ended September 30, 2023 | $185,721 |
| Research and Development Expenses (2024) | $131,919 |
| Research and Development Expenses (2023) | $161,329 |
| General and Administrative Expenses (2024) | $39,948 |
| General and Administrative Expenses (2023) | $38,492 |
| Collaboration Revenue (2024) | $2,267 |
| Collaboration Revenue (2023) | $1,479 |
| Cash, Cash Equivalents, and Marketable Securities | $218,800 |
| Accumulated Deficit | $(980,390) |
Research and Development Focus
IGM Biosciences directs substantial resources towards research and development, with a significant focus on clinical-stage programs. For the nine months ending September 30, 2024, the company reported:
| Research and Development Expense Breakdown | Value (in thousands) |
|---|---|
| Clinical Stage Programs | $40,656 |
| Preclinical Stage Programs | $19,819 |
| Personnel-related Expenses | $52,250 |
| Depreciation and Facilities | $19,194 |
Strategic Direction and Restructuring
In September 2024, IGM Biosciences announced a strategic pivot to focus exclusively on autoimmunity, which included a restructuring that aimed to reduce workforce and streamline research expenditures. The restructuring is expected to be substantially complete by June 30, 2025, with recognized charges amounting to:
| Restructuring Charges | Value (in millions) |
|---|---|
| Total Restructuring Charges (Q3 2024) | $14.0 |
| Severance and Termination Payments | $5.5 |
| Non-cash Incentive and Stock-based Compensation | $8.2 |
| Contract Termination and Other Costs | $0.3 |
Market Position and Future Outlook
With its focus on IgM antibody technology, IGM Biosciences is positioned to potentially lead in the development of novel therapies for autoimmune diseases. The company's continued investment in research and development, alongside its strategic partnerships, will be crucial for its growth and success in the competitive biotechnology landscape.
How IGM Biosciences, Inc. (IGMS) Works
Company Overview
IGM Biosciences, Inc. is a clinical-stage biotechnology company focused on the development of IgM antibodies for the treatment of various diseases, particularly in oncology and autoimmunity. The company has not yet generated revenue from product sales and primarily funds its operations through equity offerings and collaboration agreements.
Financial Performance
As of September 30, 2024, IGM Biosciences reported a net loss of $159.1 million compared to a net loss of $185.7 million for the same period in 2023. The company’s accumulated deficit stood at approximately $980.4 million.
| Financial Metric | Q3 2024 | Q3 2023 | Change |
|---|---|---|---|
| Net Loss | $61,430,000 | $61,989,000 | $559,000 |
| Collaboration Revenue | $516,000 | $509,000 | $7,000 |
| Research and Development Expenses | $46,142,000 | $54,762,000 | ($8,620,000) |
| General and Administrative Expenses | $18,761,000 | $12,507,000 | $6,254,000 |
| Total Operating Expenses | $64,903,000 | $67,269,000 | ($2,366,000) |
| Loss from Operations | ($64,387,000) | ($66,760,000) | $2,373,000 |
| Net Cash Used in Operating Activities | ($118,176,000) | ($144,223,000) | $26,047,000 |
Research and Development Expenses
For the nine months ended September 30, 2024, total research and development expenses were $131.9 million, down from $161.3 million in 2023. This decrease is attributed to lower personnel costs and reduced spending on clinical and preclinical stage programs.
| Expense Type | Q3 2024 | Q3 2023 | Change |
|---|---|---|---|
| Clinical Stage Programs | $40,656,000 | $48,177,000 | ($7,521,000) |
| Preclinical Stage Programs | $19,819,000 | $29,180,000 | ($9,361,000) |
| Personnel-related Expenses | $52,250,000 | $65,988,000 | ($13,738,000) |
| Depreciation and Facilities | $19,194,000 | $17,984,000 | $1,210,000 |
Cash Flows
For the nine months ended September 30, 2024, IGM Biosciences reported net cash used in operating activities of $118.2 million, compared to $144.2 million in 2023. The company had cash, cash equivalents, and marketable securities totaling $218.8 million as of September 30, 2024.
| Cash Flow Category | Q3 2024 | Q3 2023 |
|---|---|---|
| Cash Used in Operating Activities | ($118,176,000) | ($144,223,000) |
| Cash Provided by Investing Activities | $46,161,000 | $83,048,000 |
| Cash Provided by Financing Activities | $1,968,000 | $114,666,000 |
Stockholders’ Equity
As of September 30, 2024, IGM Biosciences had total stockholders’ equity of $78.9 million, a decrease from $203.2 million at the end of 2023. The company had 34,060,315 shares of common stock issued and outstanding.
| Equity Component | Value (in thousands) |
|---|---|
| Common Stock | $340 |
| Non-Voting Common Stock | $254 |
| Additional Paid-In Capital | $1,058,322 |
| Accumulated Other Comprehensive Income | $421 |
| Accumulated Deficit | ($980,390) |
| Total Stockholders’ Equity | $78,947 |
Recent Developments
In September 2024, IGM Biosciences announced a strategic pivot to focus exclusively on autoimmunity, which included a reduction in workforce and a reallocation of resources away from oncology programs. The company recognized restructuring charges of $14.0 million during the third quarter of 2024 as part of this shift.
How IGM Biosciences, Inc. (IGMS) Makes Money
Revenue Streams
IGM Biosciences primarily generates revenue through collaboration agreements. As of September 30, 2024, the company reported collaboration revenue of $2.3 million for the nine months ended, compared to $1.5 million for the same period in 2023. This revenue is primarily derived from a partnership with Sanofi for the development of immunology antibodies.
| Period | Collaboration Revenue (in thousands) |
|---|---|
| September 30, 2024 | $2,267 |
| September 30, 2023 | $1,479 |
Operating Expenses
Operating expenses play a significant role in the company's financials, with a total of $171.9 million reported for the nine months ended September 30, 2024, down from $199.8 million in 2023. The decrease is attributed to cost-cutting measures, including a reduction in workforce and prioritization of certain research areas.
| Expense Type | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Research and Development | $131,919 | $161,329 |
| General and Administrative | $39,948 | $38,492 |
| Total Operating Expenses | $171,867 | $199,821 |
Net Loss
As of September 30, 2024, IGM Biosciences reported a net loss of $159.1 million, a slight improvement from a net loss of $185.7 million in the same period of the previous year. This reflects the company's ongoing challenges in achieving profitability while investing heavily in research and development.
| Period | Net Loss (in thousands) |
|---|---|
| September 30, 2024 | $(159,148) |
| September 30, 2023 | $(185,721) |
Cash and Marketable Securities
As of September 30, 2024, IGM Biosciences held cash, cash equivalents, and marketable securities totaling $218.8 million, down from $423.4 million at the end of 2023. The decrease reflects the company's cash burn rate associated with its operational and developmental expenditures.
| Financial Metric | Amount (in thousands) |
|---|---|
| Cash, Cash Equivalents, and Marketable Securities | $218,800 |
| Accumulated Deficit | $(980,390) |
| Total Stockholders' Equity | $78,947 |
Future Funding Requirements
IGM Biosciences anticipates requiring additional funding to support ongoing research and development activities. The company has indicated it may pursue public or private equity offerings, debt financings, and strategic partnerships to meet these funding needs.
- Future funding will depend on:
- Clinical trial progress
- Regulatory approval timelines
- Market conditions
- The total cash burn for the nine months ended September 30, 2024, was $(118.2 million).
Stock-Based Compensation
The total stock-based compensation expense for the nine months ended September 30, 2024, was $32.6 million, compared to $37.3 million for the same period in 2023. This expense reflects the company's commitment to incentivizing its workforce amidst ongoing restructuring efforts.
| Period | Stock-Based Compensation (in thousands) |
|---|---|
| September 30, 2024 | $32,552 |
| September 30, 2023 | $37,310 |
IGM Biosciences, Inc. (IGMS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- IGM Biosciences, Inc. (IGMS) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of IGM Biosciences, Inc. (IGMS)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View IGM Biosciences, Inc. (IGMS)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.